Minimizing individual variations in arterial enhancement on coronary CT angiographs using "contrast enhancement optimizer": a prospective randomized single-center study.


Journal

European radiology
ISSN: 1432-1084
Titre abrégé: Eur Radiol
Pays: Germany
ID NLM: 9114774

Informations de publication

Date de publication:
Jun 2019
Historique:
received: 29 05 2018
accepted: 03 10 2018
revised: 20 09 2018
pubmed: 14 11 2018
medline: 6 8 2019
entrez: 14 11 2018
Statut: ppublish

Résumé

To investigate the clinical utility of our newly developed contrast enhancement optimizer (CEO) software for coronary CT angiography (CCTA). We randomly assigned 295 patients (168 males, 127 females, median age 71 years) undergoing CCTA to one of two contrast media injection protocols. Group A (n = 150) was injected with a CEO-selected iodine dose based on patient factors. In group B (n = 145), we used our standard protocol (245 mg I/kg). We recorded the CT number in the ascending aorta and determined whether the CT number was equivalent in groups A and B. For the equivalence test, we adopted 75 Hounsfield units (HU) as the equivalence margin. The standard deviation in the CT number and the rate of patients with an acceptable CT number were compared using the F test and the chi-square test, respectively. The iodine dose in group A was significantly smaller than that in group B (235.7 vs. 253.6 mg I/kg, p < 0.001). The CT number of the ascending aorta was 428.6 ± 55.5 HU in group A and 436.1 ± 68.7 HU in group B; the 95% confidence interval for the difference between the groups was -4.3 HU to 16.9 HU and within the range of the predetermined equivalence margins. In group A, the variance was significantly smaller than that in group B (p = 0.009). The number of patients with an acceptable CT number was significantly higher in group A than in group B (84.7% vs. 71.7%, p = 0.007). The use of our CEO for CCTA studies yielded optimal aortic contrast enhancement in significantly more patients than the standard protocol based on the body weight. • With our contrast enhancement optimizer (CEO) software, optimal and stable aortic enhancement can be obtained on coronary CT angiography scans irrespective of patient factors. • Management of contrast media becomes more appropriate by the CEO software. • The CEO software can control contrast enhancement at different tube voltage levels.

Identifiants

pubmed: 30421021
doi: 10.1007/s00330-018-5823-2
pii: 10.1007/s00330-018-5823-2
doi:

Substances chimiques

Contrast Media 0
iomeprol 17E17JBP8L
Iopamidol JR13W81H44

Types de publication

Journal Article

Langues

eng

Pagination

2998-3005

Références

Radiology. 2000 Feb;214(2):363-71
pubmed: 10671582
Radiology. 2001 Dec;221(3):763-7
pubmed: 11719674
Eur Radiol. 2004 Feb;14(2):178-83
pubmed: 14689227
Radiology. 2004 Jan;230(1):142-50
pubmed: 14695390
Eur Radiol. 2003 Dec;13 Suppl 5:M14-20
pubmed: 14989606
Radiology. 2004 Jun;231(3):732-6
pubmed: 15163812
Radiology. 2004 Dec;233(3):817-23
pubmed: 15516601
AJR Am J Roentgenol. 2006 Oct;187(4):W430-3
pubmed: 16985117
J Comput Assist Tomogr. 2007 Mar-Apr;31(2):272-80
pubmed: 17414766
Radiat Med. 2007 Jul;25(6):278-88
pubmed: 17634881
Radiology. 2007 Nov;245(2):475-82
pubmed: 17890356
Eur Radiol. 2008 Mar;18(3):576-83
pubmed: 17934740
Acad Radiol. 2008 Jan;15(1):49-57
pubmed: 18078906
AJR Am J Roentgenol. 2008 Jul;191(1):43-9
pubmed: 18562723
Invest Radiol. 2008 Jul;43(7):512-9
pubmed: 18580334
Eur Radiol. 2005 Dec;15 Suppl 5:E46-59
pubmed: 18637230
Eur Radiol. 2005 Dec;15 Suppl 5:E60-5
pubmed: 18637231
Heart. 2008 Nov;94(11):1386-93
pubmed: 18669550
Eur Radiol. 2009 Oct;19(10):2373-82
pubmed: 19424699
Radiol Clin North Am. 2010 Jan;48(1):9-29
pubmed: 19995627
Radiology. 2010 Jul;256(1):32-61
pubmed: 20574084
Radiol Clin North Am. 2010 Mar;48(2):237-47, vii
pubmed: 20609872
Jpn J Radiol. 2011 Aug;29(7):457-65
pubmed: 21882087
Int J Cardiovasc Imaging. 2012 Dec;28(8):2109-19
pubmed: 22212661
JAMA. 2012 Dec 26;308(24):2594-604
pubmed: 23268518
Crit Care. 2014 Nov 19;18(6):603
pubmed: 25407329
J Perinatol. 2016 Jun;36(6):481-5
pubmed: 26890553
J Comput Assist Tomogr. 2017 Mar/Apr;41(2):309-314
pubmed: 27759599
J Cardiovasc Comput Tomogr. 2016 Nov - Dec;10(6):435-449
pubmed: 27780758
PLoS One. 2018 Feb 23;13(2):e0191347
pubmed: 29474457
Acad Radiol. 2018 Oct;25(10):1298-1304
pubmed: 29599007
Radiology. 1998 Feb;206(2):455-64
pubmed: 9457200
Radiology. 1998 Jun;207(3):647-55
pubmed: 9609886
Radiology. 1998 Jun;207(3):657-62
pubmed: 9609887

Auteurs

Yoriaki Matsumoto (Y)

Department of Radiological Technology, Tsuchiya General Hospital, 3-30 Nakajima-cho, Naka-ku, Hiroshima, 730-8655, Japan. yori_8592_8592@yahoo.co.jp.
Department of Diagnostic Radiology, Graduate School of Biomedical and Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan. yori_8592_8592@yahoo.co.jp.

Toru Higaki (T)

Department of Diagnostic Radiology, Graduate School of Biomedical and Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan.

Takanori Masuda (T)

Department of Radiological Technology, Tsuchiya General Hospital, 3-30 Nakajima-cho, Naka-ku, Hiroshima, 730-8655, Japan.
Department of Diagnostic Radiology, Graduate School of Biomedical and Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan.

Tomoyasu Sato (T)

Department of Radiology, Tsuchiya General Hospital, 3-30 Nakajima-cho, Naka-ku, Hiroshima, 730-8655, Japan.

Yuko Nakamura (Y)

Department of Diagnostic Radiology, Graduate School of Biomedical and Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan.

Fuminari Tatsugami (F)

Department of Diagnostic Radiology, Graduate School of Biomedical and Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan.

Kazuo Awai (K)

Department of Diagnostic Radiology, Graduate School of Biomedical and Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH